Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Surge Laboratories (Pvt.) Ltd.

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000484 82 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx82product presentations
G38generic molecules
DF6dosage-form groups
TA9therapeutic areas
PKR82current price records
REG76registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage79%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixSurge Laboratories (Pvt.) Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/surge-laboratories-pvt-ltdGenerated 11 Aug 2026Anti-infectives44 · 54%Anesthesia & critical care10 · 12%CNS & mental health9 · 11%Fluids & supportive care8 · 10%Respiratory & allergy4 · 5%Gastrointestinal & hepatology3 · 4%Vitamins, minerals & nutrition2 · 2%Other therapeutic areas2 · 2%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioSurge Laboratories (Pvt.) Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/surge-laboratories-pvt-ltdGenerated 11 Aug 202682presentationsInjection55 · 67%Infusion10 · 12%Tablet10 · 12%Inhalation4 · 5%Suspension2 · 2%Capsule1 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionSurge Laboratories (Pvt.) Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/surge-laboratories-pvt-ltdGenerated 11 Aug 202665comparable productsBelow market median7 · 11%Near market median36 · 55%Above market median22 · 34%Company median price position+2.0%Lowest-price equivalents11Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsSurge Laboratories (Pvt.) Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/surge-laboratories-pvt-ltdGenerated 11 Aug 2026Neutro Pharma (Pvt.) Ltd.,23 shared61% overlapZafa Pharmaceutical Laboratories (P…22 shared58% overlapBio-Labs(Pvt) Ltd22 shared58% overlapM/s. Genix Pharma (Pvt) Ltd.21 shared55% overlapBosch Pharmaceuticals (Pvt) Ltd.20 shared53% overlapNabiqasim Industries (Pvt) Ltd.,18 shared47% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives44 products · 54%
Anesthesia & critical care10 products · 12%
CNS & mental health9 products · 11%
Fluids & supportive care8 products · 10%
Respiratory & allergy4 products · 5%
Gastrointestinal & hepatology3 products · 4%
Vitamins, minerals & nutrition2 products · 2%
Cardiovascular1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins18 products · 22%
Fluids, electrolytes & diluents8 products · 10%
Antimalarials7 products · 9%
Antipsychotics5 products · 6%
Local anesthetics5 products · 6%
Aminoglycoside antibacterials4 products · 5%
SSRI antidepressants4 products · 5%
Antimuscarinic bronchodilators4 products · 5%
Formulation footprint

Dosage forms

Injection55 products
Infusion10 products
Tablet10 products
Inhalation4 products
Suspension2 products
Capsule1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 SurgitecCefotaxime 8presentations 1 g, 2 g, 250 mg, 500 mg · Injection #2 EspidoneRisperidone 4presentations 1 mg, 2 mg, 3 mg, 4 mg · Tablet #3 SergifexCeftriaxone 4presentations 1 g, 2 g, 250 mg, 500 mg · Injection #4 Ventpro NebuliserIpratropium bromide 4presentations 250 mcg/mL, 500 mcg/2 mL · Inhalation #5 ArtisurgeArtesunate 3presentations 120 mg, 30 mg, 60 mg · Injection #6 CeftechCefuroxime 3presentations 1.5 g, 250 mg, 750 mg · Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median711% of comparable products
Near market median36within ±5% of median
Above market median2234% of comparable products
Lowest-price equivalents11ties included
Company median price position +2.0% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Peptiject 50 mg/2 mLRanitidine · Injection · 10's PKR 25.15/vial/unit-35.9% vs market median Prop 10 mgPropofol · Injection · 20ml PKR 23.30/mL-25.7% vs market median Prexa 5 mgEscitalopram · Tablet · 14's PKR 22.65/tablet-12.6% vs market median Sterile water for 10 mLWater for Injection · Injection · 10ml PKR 1.89/mL-6.4% vs market median Surgitec 2 gCefotaxime · Injection · 25's PKR 434.27/vial/unit-4.0% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 23shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.239 products · 98 generics 22shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 22shared generics M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 21shared generics Bosch Pharmaceuticals (Pvt) Ltd.250 products · 73 generics 20shared generics Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 18shared generics
Regulatory & price activity

Observed database signals

Registration numbers76
Price-history records88
Products with price history6
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date23 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

44 results
Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Artisurge Artesunate 120 mg Injection 1's 107247 PKR 421.19 PKR 421.19/vial/unit Near median
Artisurge Artesunate 60 mg Injection 1's 107245 PKR 252.72 PKR 252.72/vial/unit Near median
Artisurge Artesunate 30 mg Injection 1's 107246 PKR 151.63 PKR 151.63/vial/unit 6% above median
Bacip Ciprofloxacin 200 mg /100 mL IV infusion 1's 059979 PKR 280.89 PKR 280.89/vial/unit No comparator
Bacip Ciprofloxacin 100 mg/50 mL IV infusion 50ml 060755 PKR 116.48 PKR 2.33/mL Near median
Ceftech Cefuroxime 750 mg Injection 1's 044765 PKR 194.15 PKR 194.15/vial/unit Near median
Ceftech Cefuroxime 250 mg Injection 5's 044766 PKR 271.80 PKR 54.36/vial/unit Near median
Ceftech Cefuroxime 1.5 g Injection 1's 044759 PKR 349.46 PKR 349.46/vial/unit Near median
Genxat Gentamicin 80 mg/2 mL Injection 5's 057349 PKR 157.15 PKR 31.43/vial/unit No comparator
Influderm Infus Fluconazole 100 mg/50 mL IV infusion 50ml 069391 PKR 562.96 PKR 11.26/mL 12% above median
Influderm Infus Fluconazole 200 mg/100 mL IV infusion 100ml 101735 PKR 785.23 PKR 7.85/mL Near median
Intobix Metronidazole 500 mg/100 mL IV infusion 100ml 059982 PKR 189.93 PKR 1.90/mL Near median
Linox Linezolid 400 mg IV infusion 200ml 092572 PKR 776.59 PKR 3.88/mL Near median
Linox Linezolid 600 mg IV infusion 300ml 092573 PKR 1,164.88 PKR 3.88/mL Near median
Linox (Change of Brand name from Linze to Linox Linezolid 200 mg IV infusion 100ml x 1's 081841 PKR 671.75 PKR 6.72/mL Near median
Prekacin Amikacin 250 mg/2 mL Injection 1's 059975 PKR 136.31 PKR 136.31/vial/unit Near median
Prekacin Amikacin 500 mg Injection 1's 065657 PKR 258.17 PKR 258.17/vial/unit Near median
Prekacin Amikacin 100 mg /2 mL Injection 1's 059976 PKR 84.68 PKR 84.68/vial/unit No comparator
Rotem Artemether + Lumefantrine 120 mg + 20 mg Tablet 16's 045221 PKR 621.27 PKR 38.83/tablet 10% above median
Rotem Artemether 80 mg Injection 6's 029049 PKR 1,294.89 PKR 215.82/vial/unit 9% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.